The latest fund raise brings the total funding the company has received since May to $88 million, which it will use to develop CAAR-T therapies, similar to CAR-Ts used in cancers.
The company plans to file an IND in the second half of 2019. The company CEO says the "CAAR-T" therapies may avoid some of the potentially fatal toxicity risks of CAR-Ts for blood cancers.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.